Skyepharma, a French CDMO (contract development and manufacturing organization), expert in solid oral forms and complex projects, has a remarkable story to tell. Located in Saint-Quentin-Fallavier, near Lyon, the plant was acquired by the management team in 2016, expanding its expertise beyond manufacturing into pharmaceutical development, bioproduction, and handling of complex molecules such as oncological treatments, growing from 80 to over 200 employees, as well as tripling its revenue in just 9 years, following David Lescuyer’s leadership.
After 10 years successfully guiding Skyepharma’s growth, David Lescuyer, President and shareholder, is handing over leadership to Sébastien Mas, who will assume the role of the new CEO of Skyepharma. At the same time, Bertrand Simon and Hervé Letoublon become Skyepharma’s shareholders, acquiring 100% of the company’s capital via the Oleron Pharma holding and bringing new energy, strategic development expertise, and a long-term vision for Skyepharma’s growth.
Bertrand Simon, founder of BYCap, a consultancy agency renowned for its expertise in business transmission and development operations, and Hervé Letoublon, founder of Jadel (evergreen investment company : Patient Capital) and a capital-investment professional with over 20 years of experience, have chosen to invest in Skyepharma for its strong positioning, scientific know-how, and solid worldwide reputation.
“Skyepharma represents a strong foundation to accelerate its future development, with significant potential already demonstrated by its growth trajectory,” announces Bertrand Simon.
Over the past three years, Skyepharma has achieved + 33% growth, reaching a turnover of €29 million in 2024, and has built a strong and experienced team of more than 200 employees.
Thanks to his extensive experience in management and finance, Sébastien Mas will ensure the company’s continued growth while upholding Skyepharma’s core values: transparency, caring, and excellence.
This transition has been carefully prepared over the past months to ensure continuity and stability for both our teams and our partners. To support a smooth handover, David Lescuyer will continue to accompany Skyepharma during a transitional period, working closely with Sébastien and the team in the next months.
« We congratulate David and his team for their outstanding work, which has helped raise Skyepharma on the international stage,” adds Bertrand Simon.
Skyepharma’s vision and strategy remain unchanged, firmly anchored in innovation, partnership, and the pursuit of excellence that have always defined the company. The entire team remains united, experienced, and committed to serving clients with the same dedication and energy as ever.
“Skyepharma’s success relies above all on the quality of its teams and the strength of its industrial platform. We look forward to working closely together in this new phase,” concludes Bertrand Simon.
The new chapter for Skyepharma officially begins on November 6, with the official handover.
Together, we continue to write the Skyepharma story with the same passion, ambition, and spirit that have always driven us.